Successful therapeutic use of a single-dose of rituximab on relapse in adults with minimal change nephrotic syndrome

Sawara, Yukako; Itabashi, Mitsuyo; Kojima, Chiari; Tabata, Hidehiro; Kamei, Daigo; Kawanishi, Kunio; Moriyama, Takahito; Sugiura, Hidekazu; Tsukada, Misao; Takei, Takashi; Ogawa, Tetsuya; Yoshida, Takemi; Arai, Junko; Uchida, Keiko; Tsuchiya, Ken; Nitta, Kosaku

doi:10.5414/cnp72069

Cited by 23 publications

(19 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Steroid-resistant nephrotic syndrome in children remains a significant challenge. Though MCD is much less common in adults, RTX has been used with some success in case reports and small case series [87], [88] and [89]. FSGS is more common in the adult population and can be a challenge not only in the native kidney, but as recurrent disease in the renal allograft.…”

Section: Focal Segmental Glomerulosclerosis and Minimal Change Diseasementioning

confidence: 99%

Rituximab-based novel strategies for the treatment of immune-mediated glomerular diseases

Kattah¹,

Fervenza²,

Roccatello³

2013

Autoimmunity Reviews

View full text Add to dashboard Cite

Rituximab is a monoclonal antibody to the CD20 antigen on B-cells that was initially designed and approved for the treatment of non-Hodgkin's B-cell lymphoma in 1997.In the last 15 years, it has emerged as a potent immunosuppressant for many immune-mediated diseases, beginning initially with rheumatoid arthritis, and now extending into several other fields, including clinical nephrology. Based on recent large clinical trials, it is FDA-approved for the treatment of ANCA-associated vasculitis and continues to be studied in off-label usage for many glomerular diseases, including membranous nephropathy, lupus nephritis, and mixed cryoglobulinemia. It has been used as a treatment in nephrotic syndrome in children and adults, including both minimal change disease and focal segmental glomerulosclerosis. Given its efficacy, tolerability and safety profile in comparison to more conventional treatment regimens, RTX is rapidly emerging as a critical treatment modality in glomerular disease.

show abstract

Section: Focal Segmental Glomerulosclerosis and Minimal Change Diseasementioning

confidence: 99%

Rituximab-based novel strategies for the treatment of immune-mediated glomerular diseases

Kattah¹,

Fervenza²,

Roccatello³

2013

Autoimmunity Reviews

View full text Add to dashboard Cite

show abstract

“…Rituximab therapy (375 mg/m 2 body surface area per session) was administered once weekly for four weeks according to the recommended dosage for patients with B-cell lymphoma or autoimmune diseases (11,12). The successful use of singledose rituximab therapy has been reported in some patients previously exhibiting minimal changes (13)(14)(15). In patients with membranous nephropathy, four weekly infusions are generally accepted and achieve a good response (16,17).…”

Section: Table Laboratory Findings On Admissionmentioning

confidence: 99%

Rituximab Treatment for Adult Purpura Nephritis with Nephrotic Syndrome

et al. 2013

View full text Add to dashboard Cite

The case of a 68-year-old woman with purpura nephritis associated with nephrotic syndrome is herein described. The patient's clinical course and the findings of a renal biopsy study revealed purpura nephritis. Following treatment with corticosteroids and intravenous cyclophosphamide accompanied by an angiotensin II type I receptor-blocker, an anti-platelet drug and an hydroxymethylglutaryl (HMG)-CoA, the proteinuria mildly decreased. Additional rituximab therapy led to a complete remission. This report describes our successful experience using rituximab to treat refractory nephrotic syndrome of purpura nephritis. Further studies are required to confirm the efficacy of rituximab as an alternative therapy for nephrotic syndrome.

show abstract

“…[69][70][71][72][73][74][75][76][77][78][79] These studies indicate that response to treatment is associated with peripheral B cell depletion.…”

Section: Rituximabmentioning

confidence: 99%

The Treatment of Minimal Change Disease in Adults

Hogan

Radhakrishnan

2013

Journal of the American Society of Nephrology

128

123

View full text Add to dashboard Cite

Minimal change disease (MCD) is the etiology of 10%-25% of cases of nephrotic syndrome in adults. The mainstay of treatment for adult MCD, oral gucocorticoids, is based on two randomized controlled trials and extensive observational data in adults, and this treatment leads to remission in over 80% of cases. Relapses are common, and some patients become steroid-resistant (SR), steroid-dependent (SD), or frequently relapsing (FR). The data guiding the treatment of these patients are limited. Here, we review MCD in adults with particular focus on the evidence for immunosuppressive therapy in these patients.

show abstract

Successful therapeutic use of a single-dose of rituximab on relapse in adults with minimal change nephrotic syndrome

Cited by 23 publications

References 0 publications

Rituximab-based novel strategies for the treatment of immune-mediated glomerular diseases

Rituximab-based novel strategies for the treatment of immune-mediated glomerular diseases

Rituximab Treatment for Adult Purpura Nephritis with Nephrotic Syndrome

The Treatment of Minimal Change Disease in Adults

Contact Info

Product

Resources

About